Press Releases
Qureight and Avalyn Launch Strategic Partnership in Progressive Pulmonary Fibrosis
Qureight Ltd, the Core Imaging Laboratory developing deep-learning image analytics, and Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on developing inhaled therapies to treat life-threatening pulmonary diseases, today announce the initiation of a strategic partnership in progressive pulmonary fibrosis, commencing with the ongoing MIST study, a Phase...
Press Releases
Cosmo and Glenmark Announce UK MHRA Approval of Winlevi for Treatment of Acne
Dublin, Ireland and Mumbai, India | London, U.K: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Glenmark Pharmaceuticals Limited (Glenmark), a global research-led pharmaceutical company, today announced that Glenmark had received approval from the Medicines and Healthcare products...
IT & Data Management
McKesson Acquires Controlling Stake in PRISM Vision
McKesson Corporation has announced its agreement to acquire a controlling 80% interest in PRISM Vision Holdings, LLC, investing approximately $850 million to expand its leadership in retina and ophthalmology care. PRISM Vision, a leading provider of general ophthalmology and...
Drug Research
Thermo Fisher Launches Adolescent Alopecia Areata Registry
Thermo Fisher Scientific Inc., the global leader in serving science, has announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry. This initiative addresses a significant unmet need for real-world, adolescent-specific data on alopecia areata, an autoimmune...
BioPharma
Thermo Fisher Partners with X-ELIO for Renewable Energy
Thermo Fisher Scientific has taken a significant step toward achieving its sustainability goals by signing a 10-year virtual power purchase agreement (VPPA) with renewable energy developer X-ELIO. This agreement supports the Lorca solar project, which is set to become...
Clinical Trials
New Data Shows Gazyva’s Superiority in Lupus Nephritis
The New England Journal of Medicine has published detailed findings from Roche’s Phase III REGENCY trial, which demonstrated the superiority of Gazyva®/Gazyvaro® (obinutuzumab) in combination with standard therapy for treating active lupus nephritis (LN). The trial shows a compelling...
Drug Research
FDA Approves Roche’s Susvimo for Diabetic Macular Edema
Roche has announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL as the first and only continuous delivery treatment for diabetic macular edema (DME), a leading cause of vision loss in adults...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read